Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne

被引:0
|
作者
Del Rosso, James [1 ,2 ,3 ]
Gold, Linda Stein [4 ]
Tyring, Stephen [5 ]
Zeichner, Joshua [6 ]
Callender, Valerie [7 ,8 ]
Draelos, Zoe [9 ]
Werschler, William [10 ]
Cook-Bolden, Fran [11 ]
Guenin, Eric [12 ]
机构
[1] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV 89149 USA
[2] Adv Dermatol & Cosmet Surg, Maitland, FL 32751 USA
[3] Tour Univ Nevada, Henderson, NV 89014 USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Callender Dermatol & Cosmet Ctr, Glenn Dale, MD USA
[8] Howard Univ, Coll Med, Washington, DC USA
[9] Dermatol Consulting Serv PLLC, High Point, NC USA
[10] Univ Washington, Sch Med, Seattle, WA USA
[11] Weill Cornell, Dept Dermatol, New York, NY USA
[12] Ortho Dermatol, Bridgewater, NJ USA
关键词
QUALITY-OF-LIFE; TOPICAL RETINOIDS; DOUBLE-BLIND; VULGARIS; MULTICENTER; ADAPALENE; SKIN;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: While topical retinoids are a mainstay of acne treatment, acne can manifest differently in various skin types. The objective of these post hoc analyses from two pooled phase 3 studies was to examine efficacy and safety of tazarotene 0.045% and quality of life improvements in self-identified Caucasian adults with moderate-to-severe acne. Methods: In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged >= 9 years with moderateto-severe acne were randomized (1:1) to tazarotene 0.045% lotion or vehicle lotion (N=1,614); a subset of adults (>= 18 years) who selfreported Caucasian (White) race (n=645) were examined. Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment (endpoint) success (>= 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear]). Quality of life, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were also assessed. Results: At week 12, tazarotene lotion significantly reduced lesion counts by 60% (least-squares mean percent changes from baseline, tazarotene vs vehicle: inflammatory, -61.2% vs -51.1%; noninflammatory, -59.7% vs -49.3%; P<0.001, both). Significantly more participants achieved treatment success with tazarotene lotion versus vehicle (P<0.001). Numerical improvements in qualityof-life domains were observed from baseline to week 12. Most TEAEs were unrelated to treatment, and rates of moderate-to-severe erythema decreased from baseline to week 12 with tazarotene treatment. Conclusions: Tazarotene 0.045% lotion was efficacious and well tolerated over 12 weeks and led to quality-of-life improvements in Caucasian adults with moderate-to-severe acne. These results, along with those from patients with skin of color, demonstrate that once daily tazarotene 0.045% lotion is an effective and well-tolerated treatment option regardless of race or skin color.
引用
收藏
页码:1061 / 1069
页数:9
相关论文
共 50 条
  • [31] Tolerability of Tretinoin Lotion 0.05% for Moderate to Severe Acne Vulgaris: A Post Hoc Analysis in a Black Population
    Bhatia, Neal D.
    Werschler, William P.
    Cook-Bolden, Fran E.
    Guenin, Eric
    CUTIS, 2020, 106 (01): : 45 - 51
  • [32] Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Meta-Analysis
    Meher, Bikash R.
    Mishra, Archana
    Behera, Biswanath
    Ponnusamy, Subashri
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [33] Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials
    Gold, Linda Stein
    Lain, Edward
    Del Rosso, James Q.
    Gold, Michael
    Draelos, Zoe D.
    Eichenfield, Lawrence F.
    Sadick, Neil
    Werschler, William P.
    Gooderham, Melinda J.
    Lupo, Mary
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (05) : 927 - 935
  • [34] Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)
    Silverberg, Jonathan I.
    Bissonnette, Robert
    Kircik, Leon
    Murrell, Dedee F.
    Selfridge, Andrew
    Liu, Kris
    Ahluwalia, Gurpreet
    Guttman-Yassky, Emma
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (07) : 1366 - 1374
  • [35] Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis
    Qiu, Mei
    Duan, Xue-Yan
    Yin, Dao-Gen
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (01) : E24 - E26
  • [36] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    JAMA DERMATOLOGY, 2021, 157 (09) : 1047 - 1055
  • [37] Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial
    Holgate, S. T.
    Noonan, M.
    Chanez, P.
    Busse, W.
    Dupont, L.
    Pavord, I.
    Hakulinen, A.
    Paolozzi, L.
    Wajdula, J.
    Zang, C.
    Nelson, H.
    Raible, D.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (06) : 1352 - 1359
  • [38] Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population
    Kircik, Leon H.
    Baldwin, Hilary
    Lain, Edward
    Guenin, Eric
    Harris, Susan
    Bhatt, Varsha
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (02) : 178 - 188
  • [39] Efficacy and Safety of Solid-state Dual-wavelength Lasers for the Treatment of Moderate-to-severe Inflammatory Acne in Asian Populations
    Lim, Joyce Teng-Ee
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2024, 12 (01) : E5550
  • [40] Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
    Green, Lawrence J.
    Kerdel, Francisco A.
    Cook-Bolden, Fran E.
    Bagel, Jerry
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1062 - 1069